Common Contracts
2 similar Underwriting Agreement contracts by Blue Calypso, Inc., Viking Therapeutics, Inc.
Viking Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • April 8th, 2016 • Viking Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Viking Therapeutics, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of 7,500,000 shares (the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share ( “Common Stock”) and warrants to purchase an aggregate of 7,500,000 shares of Common Stock (the “Warrants,” and collectively with the Firm Shares, the “Firm Securities”). In addition, the Company proposes to grant to the Underwriters an option to purchase from the Company up to an additional 1,125,000 shares of Common Stock (the “Option Shares”) and/or Warrants to purchase up to an additional 1,125,000 shares of Common Stock (the “Option Warrants”) for the purpose of covering over-allotme
Blue Calypso, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • August 18th, 2015 • Blue Calypso, Inc. • Services-educational services • New York
The undersigned, Blue Calypso, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of [·] units (the “Firm Units”) of the Company’s securities. Each Unit consists of [·] share[s] of the Company’s Common Stock, $0.0001 par value per share (“Common Stock”) and [·] warrant[s] (each, a “Warrant”), with each Warrant representing the right to purchase [·] share[s] of Common Stock at a purchase price of [ % of the per share offering price]. In addition, the Company proposes to grant to the Underwriters an option to purchase from the Company up to an additional [·] units for the purpose of covering over allotments in connection with the sale of the Firm Units (collectively, the “Opti
